Clinical trials: CV Risk
Type 2 Diabetes
Transform CV Risk in Diabetes
This initiative supports a real-world study of practice and physician prescribing patterns and a quality improvement initiative evaluating best practices (including clinical decision support, facilitated referral to…
- Trial name
- CVRiD (NCT05948969)
- Testing
- Decision support, Facilitated referral to a cardiometabolic team-based center
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- American College of Cardiology
Acute Coronary Syndrome
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE-2 (NCT05918861)
- Testing
- Dalcetrapib
- Where
- 231 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- DalCor Pharmaceuticals
Rheumatoid Arthritis (RA, Oxidative Stress
Oxidative Stress and Cardiovascular Risk in Patients With Rheumatoid Arthritis
The pathogenic process underlying atherosclerosis resembles a chronic inflammatory response in which oxidative stress is involved.
- Conditions
- Rheumatoid Arthritis (RA, Oxidative Stress, Cardiovascular (CV) Risk
- Trial name
- PIFIISC23/07 (NCT07760662)
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- University of La Laguna
Type 1 Diabetes (T1D)
Circadian Mechanisms, Glucose, and CV Risks in T1D
People with type 1 diabetes are disproportionately affected by cardiovascular disease (CVD). Short and irregular sleep have been associated with cardiovascular risk in this population.
- Trial name
- NCT06624046
- Testing
- Sleep stability intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois at Chicago